Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease

Journal of Intensive Care Medicine

Volumn 23, Issue 5, 2008, Pages 329-334

  Lee, Jaclyn E ^a   Hillier, Simon C ^b   Knoderer, Chad A ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Congenital heart disease; Nitric oxide; Pediatrics; Sildenafil

Indexed keywords

NITRIC OXIDE; SILDENAFIL;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; CONGENITAL HEART DISEASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPOTENSION; INFANT; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MEDICAL RECORD REVIEW; NEWBORN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; COHORT STUDIES; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; POSTOPERATIVE COMPLICATIONS; PURINES; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; SULFONES;

EID: 51849087407     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608321389     Document Type: Article

References (24)

1. Rosenzweig EB, Widlitz AC, Barst RJ Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004 ; 38 (1). 2-22.
2. Tulloh R. Management and therapeutic options in pediatric pulmonary hypertension. Expert Rev Cardiovasc Ther. 2006 ; 4 (3). 361-374.
3. Celermajer DS, Cullen S., Deanfield JE Impairment of endothelium- dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993 ; 87 (2). 440-446.
4. Schulze-Neick I., Li J., Penny DJ, Redington AN Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg. 2001 ; 121 (6). 1033-1039.
5. Wessel DL, Adatia I., Giglia TM, Thompson JE, Kulik TJ Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993 ; 88 (5 Pt 1). 2128-2138.
6. Brown KL, Ridout DA, Goldman AP, Hoskote A., Penny DJ Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med. 2003 ; 31 (1). 28-33.
7. Bando K., Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996 ; 112 (6). 1600-1607 ; discussion 1607-1609.
8. Curran RD, Mavroudis C., Backer CL, Sautel M., Zales VR, Wessel DL Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg. 1995 ; 60 (6). 1765-1771.
9. Miller OI, Tang SF, Keech A., Pigott NB, Beller E., Celermajer DS Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet. 2000 ; 356 (9240). 1464-1469.
10. Russell IA, Zwass MS, Fineman JR, et al. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg. 1998 ; 87 (1). 46-51.
11. Beavo JA Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995 ; 75 (4). 725-748.
12. Reffelmann T., Kloner RA Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003 ; 108 (2). 239-244.
13. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002 ; 124 (3). 628-629.
14. Atz AM, Wessel DL Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999 ; 91 (1). 307-310.
15. Erickson S., Reyes JT, Adatia I. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am Coll Cardiol. 2002 ; 39 (Suppl 2). 402.
16. Namachivayam P., Theilen U., Butt WW, Cooper SM, Penny DJ, Shekerdemian LS Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006 ; 174 (9). 1042-1047.
17. Assreuy J., Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol. 1993 ; 108 (3). 833-837.
18. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993 ; 73 (5). 808-812.
19. Ravichandran LV, Johns RA, Rengasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol. 1995 ; 268 (6 Pt 2). H2216 - H2223.
20. Pearl JM, Nelson DP, Raake JL, et al. Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med. 2002 ; 30 (1). 89-93.
21. Mychaskiw G., Sachdev V., Heath BJ Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth. 2001 ; 13 (3). 218-220.
22. Saygili A., Canter B., Iriz E., et al. Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. J Cardiothorac Vasc Anesth. 2004 ; 18 (6). 775-776.
23. Schulze-Neick I., Hartenstein P., Li J., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003 ; 108 (Suppl 1). 11167-11173.
24. Stocker C., Penny DJ, Brizard CP, Cochrane AD, Soto R., Shekerdemian LS Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 2003 ; 29 (11). 1996-2003.